Shares of clinical stage biotechnology company Longeveron Inc. (LGVN) are rising more than 20% Tuesday morning at $3.89.
Longeveron today reported long-term follow-up data from the Company’s ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS).
The data showed that 100% of the 10 patients who participated in the ELPIS I trial survived and remained heart transplant-free for up to 5 years of age after receiving Lomecel-BTM during their Stage 2 surgery.
LGVN has traded in the range of $2.50 – 9.34 in the last 1 year.
Source: Read Full Article
Lates News:
-
$BTC: Former SEC Enforcement Attorney Explains Why “Bitcoin’s Price Is Rising”
-
Hibbett Shares Rally On Better-than-estimated Earnings, Increased Outlook
-
Gold Advocate Peter Schiff Embraces Bitcoin NFTs
-
Coinbase to Launch Institutional BTC and ETH Futures
-
Barbie Star's Bitcoin Remarks Ignite Discussions in Crypto World